Molecular Insight Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. The company develops its lead radiotherapeutic oncology product candidate, Azedra, which is in pivotal Phase IIb trials for the treatment of pheochromocytoma/paraganglioma in adults and neuroblastoma in children; and its lead radiotherapeutic product candidate, Onalta, which is in European pivotal Phase III clinical studies for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. Molecular Insight Pharmaceuticals also develops Trofex, a molecular imaging radiopharmaceutical product candidate in Phase I trials for the diagnosis and detection of metastatic prostate cancer; and Solazed, a targeted radiotherapeutic under Phase I initialization, for the treatment of malignant metastatic melanoma. In addition, it is developing a non-oncology product, Zemiva, a molecular cardiovascular imaging radiopharmaceutical product candidate, which completed the Phase II trials for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart muscle. Molecular Insight Pharmaceuticals sub-licensed Onalta to BioMedica Life Sciences S.A. for development in certain countries in Europe, the Middle East, north Africa, Russia, and Turkey under a strategic collaboration agreement. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003. Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts.